Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) is facing multiple challenges, including tax payment issues, stock manipulation by its actual controller Zhao Yeqing, and declining financial performance, raising concerns about the company's future stability and management effectiveness [2][9]. Group 1: Tax Issues - Jincheng Jinsu Pharmaceutical Co., Ltd. and its subsidiary Guangdong Landu Pharmaceutical Co., Ltd. were required to pay a total of 21.5968 million yuan in back taxes and penalties due to tax issues from 2017 to 2018 [3]. - The tax payments have been completed as of the announcement date, and a supplementary agreement was signed to revise tax liability clauses related to the tax recovery [5]. Group 2: Stock Manipulation - Zhao Yeqing, the actual controller of Jincheng Pharmaceutical, was involved in stock manipulation from August 2017 to February 2020, using 104 accounts to trade the company's stock, which led to a fine and a four-year market ban [7][8]. - The manipulation involved significant trading activity, with 1.19 billion shares bought and 1.07 billion shares sold, resulting in a loss of 7.392 million yuan for the involved accounts [8]. Group 3: Financial Performance - Jincheng Pharmaceutical's financial performance has been declining, with a revenue of 35.38 billion yuan in 2023, a growth rate of only 0.93%, and a net profit decrease of 36.09% to 1.75 billion yuan [9]. - In the first three quarters of 2025, the company reported a revenue of 19.32 billion yuan, down 23.19%, and a net profit of 31.5771 million yuan, down 79.1% [9]. - The company experienced a significant decline in its gross margin to 36.23%, a decrease of 3.9 percentage points, and a net margin of 1.74%, down 4.71 percentage points compared to the previous year [9].

证券代码：300233 证券简称：金城医药 公告编号：2025-089 山东金城医药集团股份有限公司 检查范围：原料药乳糖酸红霉素，一车间，乳糖酸红霉素生产线 关于子公司收到药品 GMP 符合性检查告知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司全资子公司北京金城泰尔制药有限公司（以 下简称"金城泰尔"）收到北京市药品监督管理局核准签发的《药品 GMP 符合性 检查告知书》（京药监药 GMP〔2025〕020107），其申报的乳糖酸红霉素原料药 已通过《药品生产质量管理规范（2010 年修订）》符合性检查（以下简称"GMP 符合性检查"）。现将有关情况公告如下： 一、《药品 GMP 符合性检查告知书》相关信息 企业名称：北京金城泰尔制药有限公司 检查地址：河北省沧州市临港经济技术开发区西区北京医药产业园经五路以 东纬二路以北 检查时间：2025 年 10 月 28 日至 10 月 31 日 检查结论：根据本次检查情况，经审查，该企业此次检查范围符合《药品生 产质量管理规范 (2010 年修订) 》和附录要求。 二、产品 ...

Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received the GMP compliance inspection notice for the active pharmaceutical ingredient Mirabegron, allowing for domestic production and sales [1] Group 1: Company Developments - The approval from the Beijing Drug Administration signifies that the Mirabegron active pharmaceutical ingredient has passed the GMP compliance inspection, which is based on the 2010 revised Drug Production Quality Management Standards [1] - This achievement enhances the variety of products offered by the company and is expected to improve its competitiveness in the chemical raw material drug sector [1] - Jincheng Tail will proceed with production in accordance with relevant requirements and market demand [1]

Company Announcements - Tianpu Co., Ltd. has seen a cumulative increase of 718.39% in stock price from August 22 to December 30, leading to a suspension for verification starting December 31, 2025 [1] - Dongjie Intelligent has terminated its major asset restructuring plan and will resume trading on December 31, 2025 [2] - Zijin Mining expects a net profit increase of 59%-62% for 2025, with significant increases in the sales prices of gold, copper, and silver [2] - Jinpan Technology signed a contract for an overseas data center project worth approximately 696 million yuan [3] - Yanhai Co., Ltd. plans to acquire 51% of Wenkang Salt Lake for 4.605 billion yuan to enhance its salt lake industry base [5] - Shengxin Lithium Energy intends to acquire 30% of Qicheng Mining for 2.08 billion yuan, which is developing a lithium mine with an annual capacity of 3 million tons [7] - Mingde Bio plans to acquire 100% of Wuhan Bikaier Rescue Supplies Co., Ltd. in a significant asset restructuring [8] - Guotou Zhonglu plans to issue shares to acquire 100% of China Electronics Engineering Design Institute for 6.026 billion yuan [9] - Zhaoxing Co., Ltd. plans to invest 1.53 billion yuan in intelligent robotics and high-precision components for automotive applications [10] Stock Movements - Chaojie Co., Ltd. reported a reduction of 3.00% in shares by its controlling shareholder from November 25 to December 29, 2025 [6] - Five Continents New Spring's third-largest shareholder reduced holdings by 2.73% from November 3 to December 29, 2025 [13] - Zhongju Gaoxin plans to repurchase shares worth 300 million to 600 million yuan for capital reduction [20] Contracts and Projects - Zhejiang Construction signed an 18 billion yuan construction contract for a campus project [23] - Shen Si Electronics won a 199.8 million yuan project for low-altitude flight management services in Jinan [24] - Wangfujing signed a contract for a duty-free project at Beijing Capital International Airport, with a minimum operating fee of 113 million yuan [25] Investments and Financing - Tianyuan Co., Ltd. plans to invest 1.483 billion yuan in a titanium dioxide project [15] - Zhongke Co., Ltd. plans to invest 1.741 billion yuan in an expansion project for lead-zinc mining [16] - Zongheng Co., Ltd. plans to raise up to 548 million yuan for drone systems and AI technology projects [26]

Core Viewpoint - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received the GMP compliance inspection notice from the Beijing Drug Administration for its active pharmaceutical ingredient, Mirabegron, indicating successful compliance with the 2010 revised Good Manufacturing Practice standards [1] Group 1 - The inspection took place from December 11 to 15, 2023 [1] - The scope of the inspection covered the Mirabegron production line in the second workshop [1] - The inspection conclusion confirmed that the company met the relevant standards and appendix requirements [1]

Core Viewpoint - Jincheng Pharmaceutical announced the approval of a supplementary agreement by its sixth board of directors during the 20th meeting [2] Group 1 - The company held its 20th meeting of the sixth board of directors [2] - The meeting resulted in the approval of a proposal regarding the signing of a supplementary agreement [2]

关于子公司收到药品 GMP 符合性检查告知书的公告 证券代码：300233 证券简称：金城医药 公告编号：2025-088 山东金城医药集团股份有限公司 二、产品相关情况 米拉贝隆是一种β-3 肾上腺素受体的激动剂，主要用于治疗包括尿失禁、 尿急和尿频在内的膀胱过度活动症（OAB）。目前包括公司在内国内有 19 家企业 的米拉贝隆批文在原料药登记平台上状态为 A。根据 IMS 数据查询，2022 年至 2024 年米拉贝隆原料药全球消耗量分别为 57.91 吨、63.05 吨和 69.79 吨；2022 年至 2024 年米拉贝隆制剂全球销售额分别为 32.86 亿美元、34.20 亿美元和 35.36 亿美元。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司全资子公司北京金城泰尔制药有限公司（以 下简称"金城泰尔"）收到北京市药品监督管理局核准签发的《药品 GMP 符合性 检查告知书》（京药监药 GMP〔2023〕020113），其申报的米拉贝隆原料药已通 过《药品生产质量管理规范（2010 年修订）》符合性检查（以下简称"GM ...

二、董事会会议审议情况 证券代码：300233 证券简称：金城医药 公告编号：2025-086 山东金城医药集团股份有限公司 第六届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东金城医药集团股份有限公司（以下简称"公司"或"金城医药"）第六届 董事会第二十次会议通知于 2025 年 12 月 26 日以邮件、电话通知方式发出。本次 董事会会议于 2025 年 12 月 30 日以书面传签方式召开。会议应参加董事 8 名，实 际参加董事 8 名。会议由董事长李家全先生召集，会议的召开和表决程序符合《中 华人民共和国公司法》和《公司章程》的有关规定。 2025 年 12 月 30 日 山东金城医药集团股份有限公司董事会 1、审议通过《关于签署<股权转让协议>之补充协议的议案》。 经董事会审议，同意公司与傅苗青、周白水签署《山东金城医药集团 股份有限公司与傅苗青、周白水之股权转让协议》之补充协议，就公司向 其追偿事项达成一致意见。具体内容详见公司在巨潮资讯网上披露的《关 于签署<股权转让协议>之补充协议的公告 ...

证券代码：300233 证券简称：金城医药 公告编号：2025-087 山东金城医药集团股份有限公司 关于签署《股权转让协议》之补充协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、基本情况 2025年12月28日，山东金城医药集团股份有限公司（以下简称"金城医药"或"公 司"或"甲方"）披露了《关于子公司补缴税款的公告》。2025年12月30日，公司第六 届董事会第二十次会议审议通过了《关于签署<股权转让协议>之补充协议的议案》。公司 与傅苗青、周白水就金城金素及榄都药业补缴税款情况进行了沟通并就公司向其追偿事项 签署《补充协议》。 二、补充协议的主要内容 甲方（受让方）：山东金城医药集团股份有限公司 身份证号：3302111977****1530 以上甲方、乙方合称为"双方"，分别或单独称为"一方"；乙方1、乙方2合称为 "乙方"；目标公司指浙江磐谷药源有限公司。 第一条 原协议条款的修订 双方一致同意，原协议第九条"乙方的陈述、保证及承诺"中第9.19条"除已向甲 方披露的情况外，目标公司及金城金素遵守有关税务法律法规规定，依法缴纳税款，如 ...

Group 1 - The core viewpoint of the news is that Jincheng Pharmaceutical has experienced a decline in stock price and trading volume, with significant changes in financing and shareholder structure [1][2][3] Group 2 - As of December 29, Jincheng Pharmaceutical's stock price fell by 0.84%, with a trading volume of 91.98 million yuan [1] - The financing data shows that on the same day, the company had a financing buy-in of 10.52 million yuan and a financing repayment of 15.90 million yuan, resulting in a net financing outflow of 5.38 million yuan [1] - The total financing and securities lending balance for Jincheng Pharmaceutical is 384 million yuan, which accounts for 7.06% of its circulating market value, indicating a low financing level compared to the past year [1] - The company repaid 2,900 shares in securities lending on December 29, with a remaining securities lending balance of 5.53 million yuan, also reflecting a low level compared to the past year [1] Group 3 - As of December 20, the number of shareholders for Jincheng Pharmaceutical increased to 27,500, while the average circulating shares per person decreased by 2% to 13,492 shares [2] - For the period from January to September 2025, Jincheng Pharmaceutical reported a revenue of 1.932 billion yuan, a year-on-year decrease of 23.19%, and a net profit attributable to shareholders of 31.58 million yuan, down 79.10% year-on-year [2] Group 4 - Jincheng Pharmaceutical has distributed a total of 933 million yuan in dividends since its A-share listing, with 323 million yuan distributed in the last three years [3] - As of September 30, 2025, the top ten circulating shareholders include new entrants such as the Fortune Precision Medical Flexible Allocation Mixed Fund, holding 4.961 million shares, and the Xingquan Light Asset Mixed Fund, holding 3 million shares [3] - The Hong Kong Central Clearing Limited, ranked as the eighth largest circulating shareholder, reduced its holdings by 2.135 million shares to 3.336 million shares [3]